Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/101862
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Reis, A . J. | - |
dc.contributor.author | Alves, C. | - |
dc.contributor.author | Furtado, S. | - |
dc.contributor.author | Ferreira, J. | - |
dc.contributor.author | Drummond, M. | - |
dc.contributor.author | Robalo-Cordeiro, C. | - |
dc.date.accessioned | 2022-09-19T08:14:23Z | - |
dc.date.available | 2022-09-19T08:14:23Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 25310437 | pt |
dc.identifier.uri | https://hdl.handle.net/10316/101862 | - |
dc.description.abstract | Chronic Obstructive Pulmonary Disease (COPD) is a serious pulmonary condition. Many patients experience exacerbations and some require Emergency Room visits and hospitalization. In Portugal, hospitalizations due to COPD between 2009 and 2016 decreased by 8%, but they still represented 8049 hospitalized patients in 2016. Appropriate management of COPD exacerbations presents a clinical challenge and, in order to guide therapy, it is important to identify the underlying cause; however, this is not possible in about a third of severe COPD exacerbations. There are several diagnostic tools that can be used to assess an exacerbation and its severity, which will in turn guide treatment, and prognostic scores should be used to predict the risk of future exacerbations. After an exacerbation is appropriately managed, a suitable discharge plan should be prepared. This should generally include reclassification of the patient according to GOLD criteria, optimization of pharmacological therapy, management of comorbidities, patient (or caregiver) education on the correct use of medications, referral to a Pulmonology Outpatient Clinic, if they are not already attending one, and a smoking cessation and respiratory rehabilitation program. In this paper, we will focus on the pharmacological strategies for the management of COPD exacerbations, risk stratification and a hospital discharge plan proposal. | pt |
dc.language.iso | eng | pt |
dc.relation | Novartis Portugal | pt |
dc.rights | openAccess | pt |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | pt |
dc.subject | COPD | pt |
dc.subject | Exacerbation | pt |
dc.subject | Hospitalization | pt |
dc.subject | Management | pt |
dc.subject | Discharge | pt |
dc.subject.mesh | Aftercare | pt |
dc.subject.mesh | Disease Progression | pt |
dc.subject.mesh | Humans | pt |
dc.subject.mesh | Pulmonary Disease, Chronic Obstructive | pt |
dc.subject.mesh | Severity of Illness Index | pt |
dc.subject.mesh | Patient Discharge | pt |
dc.title | COPD exacerbations: management and hospital discharge | pt |
dc.type | article | - |
degois.publication.firstPage | 345 | pt |
degois.publication.lastPage | 350 | pt |
degois.publication.issue | 6 | pt |
degois.publication.title | Pulmonology | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 10.1016/j.pulmoe.2018.06.006 | pt |
degois.publication.volume | 24 | pt |
dc.date.embargo | 2018-01-01 | * |
uc.date.periodoEmbargo | 0 | pt |
item.languageiso639-1 | en | - |
item.fulltext | Com Texto completo | - |
item.grantfulltext | open | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.openairetype | article | - |
item.cerifentitytype | Publications | - |
crisitem.project.grantno | A Novartis foca a sua atividade em duas divisões com poder de inovação e dimensão global: farmacêutica e medicamentos genéricos e biossimilares- Portugal | - |
crisitem.author.researchunit | iNOVA4Health - Programme in Translational Medicine (iBET, CEDOC/FCM, IPOLFG and ITQB) | - |
crisitem.author.orcid | 0000-0002-8264-3856 | - |
Appears in Collections: | FMUC Medicina - Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1-s2.0-S2531043718301077-main.pdf | 692.01 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
15
checked on Nov 4, 2024
WEB OF SCIENCETM
Citations
17
checked on Nov 2, 2024
Page view(s)
123
checked on Nov 5, 2024
Download(s)
77
checked on Nov 5, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License